Q-omics provides the consensus-scored MIR3183 profile across patient tissues and cancer cell-line models. MIR3183 expression is associated with patient survival in 17 of 34 cancer types, with the highest sampling consensus in STAD. Among the 18 cancer types available for tumor–normal comparison, MIR3183 is differentially expressed in 5, with the highest sampling consensus in COAD. Additionally, MIR3183 RNA expression shows 10,150 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight STAD, COAD, and UVM as cancer lineages where MIR3183 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MIR3183 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MIR3183 survival associations across molecular data types. MIR3183 RNA expression shows survival associations in the most cancer types (17). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MIR3183 RNA expression–survival associations across cancer types. High MIR3183 expression shows unfavorable associations in COAD, THCA, ACC and LIHC, but favorable associations in STAD and LUAD. The STAD Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .002). Together, the overview and detailed table identify STAD as the clearest survival context for MIR3183 RNA expression.
This table summarizes MIR3183 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for MIR3183. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MIR3183 shows lower tumor expression in LUSC and higher tumor expression in COAD, STAD, BLCA and PRAD. The COAD box plot shows higher MIR3183 RNA expression in tumor versus normal tissue (log2 FC = +0.281, t-test p = .033).
This table shows molecular features associated with MIR3183 in patient tissues and cancer cell lines. In patient samples, MIR3183 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set.
